Last checked at 14 Dec 2015 07:56
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF SECURITIES.
DISCUSSIONS WITH ACERTA PHARMA BV
Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.
The Company will make a further announcement if and when appropriate.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
|
| |
Esra Erkal-Paler
| UK/Global | +44 20 7604 8030 |
Neil Burrows | UK/Global | +44 20 7604 8032 |
Vanessa Rhodes
| UK/Global | +44 20 7604 8037 |
Karen Birmingham | UK/Global | +44 20 7604 8120 |
Jacob Lund
| Sweden | +46 8 553 260 20 |
Michele Meixell | US | +1 302 885 2677 |
Investor Enquiries | ||
UK | ||
Thomas Kudsk Larsen
| Oncology | +44 7818 524185 |
Eugenia Litz | RIA
| +44 7884 735627 |
Nick Stone | CVMD
| +44 7717 618834 |
Craig Marks | Finance | +44 7881 615764 |
Christer Gruvris
| Consensus Forecasts | +44 7827 836825 |
US | ||
Lindsey Trickett | Oncology, ING | +1 240 543 7970 |
Mitch Chan | Oncology | +1 240 477 3771 |
Dial / Toll-Free | +1 866 381 7277 |
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal
14 December 2015
-ENDS-